Science Immunology, published by the American Association for the Advancement of Science, is a leading journal in the field of immunology, recognized for its significant impact and rigor in advancing our understanding of immune responses and complex diseases. With an impressive impact factor that places it in the Q1 category of both immunology and allergy, as well as miscellaneous medicine, this journal is ranked #7 and #8 in their respective Scopus categories, reflecting its high-quality research output. Since its inception in 2016, Science Immunology has been at the forefront of interdisciplinary immunological research, fostering crucial insights that link immunology with pressing health challenges. The journal is committed to providing open access to its content, ensuring that groundbreaking findings are accessible to a global audience of researchers, professionals, and students. Its anthology not only addresses fundamental immunological mechanisms but also enhances the dialogue on translational applications and therapeutic interventions, solidifying its position as an essential resource within the scientific community.

Immunopharmacology and Immunotoxicology, published by Taylor & Francis Ltd, is a distinguished academic journal with a focus on the interrelation between pharmacology, immunology, and toxicology. Established in 1978, the journal serves as a vital platform for the dissemination of cutting-edge research aimed at enhancing the understanding of immunologically mediated drug responses and toxic effects. The journal encompasses a broad scope of topics relevant to the fields of immunology, pharmacology, and toxicology, offering insights that are pivotal for both academia and the pharmaceutical industry. With a commendable 2023 impact factor and ranking in Q3 in Immunology and Q2 in both Pharmacology and Toxicology, it holds a respected position within its categories, making it a valuable resource for researchers, professionals, and students seeking to stay abreast of the latest developments in the field. The journal is accessible through traditional subscription models and encourages submissions that bring forth innovative findings that might influence therapeutic strategies and public health.

IMMUNOBIOLOGY is a prestigious academic journal published by Elsevier GmbH that significantly contributes to the fields of hematology and immunology. With its ISSN 0171-2985 and E-ISSN 1878-3279, this journal has been disseminating impactful research since 1979, positioning itself at the forefront of immunological and hematological advances. The journal holds a commendable ranking of Q2 in Hematology and Q3 in both Immunology and Immunology and Allergy, indicating its relevance and influence within the scientific community, as reflected by its Scopus rankings. Although IMMUNOBIOLOGY operates under a subscription model, it remains dedicated to expanding knowledge across disciplines, fostering innovative research, and facilitating connections among researchers, professionals, and students. Situated in Munich, Germany, this journal is continually evolving and aims to remain an essential resource for the latest discoveries and insights in the realms of immunity and blood disorders, ultimately enhancing our understanding of complex biological systems.

INFLAMMOPHARMACOLOGY is a premier journal published by SPRINGER BASEL AG, specializing in the evolving fields of immunology and pharmacology. Established in 1991, the journal has made significant strides in contributing to the understanding of inflammation-related disorders, therapeutic innovations, and the pharmacological implications associated with these conditions. With an impressive Q2 ranking in Immunology and Q1 rankings in both Pharmacology and Medical Pharmacology for 2023, alongside notable Scopus rankings, INFLAMMOPHARMACOLOGY maintains its position at the forefront of scientific research. The journal provides a vital platform for researchers and practitioners to disseminate groundbreaking findings and explore novel approaches in therapeutics, reinforcing the importance of evidence-based medicine. Accessible exclusively through traditional subscription options, it continues to attract a diverse readership invested in advancing knowledge within these cutting-edge disciplines.

Central European Journal of Immunology is a premier publication dedicated to advancing the field of immunology and allergy research. Established in 1996 and published by TERMEDIA PUBLISHING HOUSE LTD, this open access journal has consistently provided a platform for innovative research and comprehensive reviews since its transition to open access in 2002. With an ISSN of 1426-3912 and E-ISSN of 1644-4124, it embraces a global readership while being rooted in Poland. The journal, with a notable Q3 ranking in both the categories of immunology and allergy in 2023, positions itself within the competitive landscape of scientific discourse, as reflected in its Scopus rankings. Designed for researchers, professionals, and students, the Central European Journal of Immunology not only disseminates significant findings but also fosters collaboration and innovation in the immunological sciences, making it a vital resource for those seeking to stay current in this rapidly evolving field.

HUMAN IMMUNOLOGY, published by Elsevier Science Inc, serves as a critical platform for disseminating research in the fields of immunology and allergy, as well as various aspects of miscellaneous medicine since its inception in 1980. With an ISSN of 0198-8859 and E-ISSN 1879-1166, this journal is pivotal for researchers and practitioners looking to advance their understanding of human immune responses and related conditions. The journal currently holds a respectable position within its field, as highlighted by its 2023 Scopus ranks—#114/233 in Immunology and Allergy and #132/236 in Immunology and Microbiology. Moreover, it maintains a Q2 quartile ranking in both Immunology and Allergy and miscellaneous Medicine, underscoring its influence and reach within the scientific community. Although it does not currently offer Open Access options, HUMAN IMMUNOLOGY remains dedicated to providing valuable insights and fostering academic discourse within its discipline, characterized by a rigorous peer-review process and a focus on innovative research trajectories.

Cancer Immunology Immunotherapy, published by Springer, stands as a premier journal in the fields of cancer research and immunology, holding a prestigious Q1 ranking across multiple categories, including Oncology and Medicine as of 2023. With an ISSN of 0340-7004 and an E-ISSN of 1432-0851, this journal has been a pivotal platform for groundbreaking research since its inception in 1976, continuing to provide insight into the complex interactions between the immune system and cancer. The journal's scope encompasses a wide array of topics, including novel therapeutic strategies, immunological mechanisms, and translational science aimed at advancing treatment outcomes for cancer patients. Renowned for its rigorous peer-review process and high impact factor, it attracts contributions from leading experts and researchers around the globe, positioning itself among the top-tier publications with Scopus rankings that reflect its vital role in advancing the field. Access options are generally subscription-based, ensuring a comprehensive resource for professionals and academics seeking to deepen their understanding and make meaningful contributions to cancer immunotherapy.

CELLULAR IMMUNOLOGY is a prestigious journal published by Academic Press Inc. Elsevier Science, dedicated to advancing the field of immunology. Established in 1970 and converging ongoing research up to 2024, this journal has carved out a significant niche within the academic community, boasting a notable Q2 ranking in the Immunology category and holding a respectable 67th percentile ranking within Scopus for its contributions to the disciplines of Immunology and Microbiology. The journal serves as a vital platform for disseminating high-quality research, reviews, and methodologies that elucidate the intricacies of cellular immune responses, thereby benefiting researchers, professionals, and students alike. Although it does not offer open access, the journal's impact is evidenced by its comprehensive coverage of pioneering studies and ongoing developments in the immunological sciences, positioning it as an essential resource for those seeking to deepen their understanding and engage with the latest findings in cellular immunology.

INTERNATIONAL IMMUNOLOGY, published by OXFORD UNIV PRESS, stands out as a premier journal in the field of immunology, providing a vital platform for disseminating groundbreaking research and innovative developments within the discipline. With an impressive Q1 ranking in Immunology and Allergy, as well as in Medicine (miscellaneous), it consistently showcases high-impact studies that contribute to the advancement of immunological knowledge. The journal spans over three decades, from its inception in 1989 to its ongoing contributions as of 2024, thus solidifying its reputation in the scientific community. Researchers, professionals, and students will find valuable articles that delve into the complexities of immune responses, therapeutic interventions, and emerging immunological paradigms, ensuring INTERNATIONAL IMMUNOLOGY remains at the forefront of knowledge in the life sciences.

TRENDS IN IMMUNOLOGY, published by CELL PRESS, stands as a premier source of insights and developments within the field of immunology. With an ISSN of 1471-4906 and E-ISSN of 1471-4981, this journal has established a strong reputation, evidenced by its prestigious status in Q1 quartiles for both Immunology and Allergy in 2023. It is ranked #13 out of 233 in the Scopus category of Medicine – Immunology and Allergy, and #16 out of 236 in Immunology and Microbiology, placing it within the top 94th and 93rd percentiles respectively. Since its inception in 1987, TRENDS IN IMMUNOLOGY has provided a critical platform for researchers, professionals, and students to access the latest advancements and integrative reviews in immunological research. The journal offers open access options, enhancing the accessibility of its high-impact content to a global audience. Researchers and practitioners rely on its pages not only for cutting-edge findings but also for comprehensive discussions that drive the future of immunology research.